Loading…
Cancer Care Payment Reform Act of 2016
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Cancer Care Payment Reform Act of 2016 This bill amends title XVIII (Medicare) of the Social Security Act to establish the Oncology Medical Home Demonstration Project, through which the Centers for Medicare & Medicaid Services (CMS) shall make special payments to participating oncology practices that coordinate patient care and meet other specified requirements. During the first two years of the project, CMS shall pay a care coordination management fee to each such practice. After the third, fourth, and fifth years of the project, CMS shall pay a performance incentive payment to each participating practice that meets or exceeds performance standards developed by CMS. CMS shall assess the performance of each participating oncology practice annually. Performance standards shall address: (1) specified measures related to patient care, resource utilization, survivorship, and end-of-life care; and (2) the patient experience of care, as reflected in surveys submitted by each practice. CMS shall also assess the extent to which a practice has used breakthrough or other best-in-class therapies. To the extent practicable, CMS shall select practices of varying sizes and geographic areas for participation.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2017 · second_quarter · Health Issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S5163-5165)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $730,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Client expense: $700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
H.R. 1934- Cancer Care Payment Reform Act of 2015 Medicare Part B reimbursement Part B drug payment model S.3211- Cancer Care Payment Reform Act of 2016
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934; S. 3211). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care. General discussion on the CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement. Specific legislation to stop the Medicare Part B Drug Payment Model (H.R. 5122). Topics related to pharmaceutical benefit managers (PBMs)
Client expense: $112,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934; S. 3211). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care. General discussion on the CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement. Specific legislation to stop the Medicare Part B Drug Payment Model (H.R. 5122).
Client expense: $174,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
H.R. 1934- Cancer Care Payment Reform Act of 2015 Medicare Part B reimbursement Part B drug payment model S.3211- Cancer Care Payment Reform Act of 2016
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
H.R. 1934- Cancer Care Payment Reform Act of 2015 Medicare Part B reimbursement Part B drug payment model S.3211- Cancer Care Payment Reform Act of 2016
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE